Literature DB >> 8823501

Comparative serum protein binding of anthracycline derivatives.

O Chassany1, S Urien, P Claudepierre, G Bastian, J P Tillement.   

Abstract

The binding of doxorubicin, iododoxorubicin, daunorubicin, epirubicin, pirarubicin, zorubicin, aclarubicin, and mitoxantrone to 600 microM human serum albumin and 50 microM alpha 1-acid glycoprotein was studied by ultrafiltration at 37 degrees C and pH 7.4. Anthracycline concentrations (total and free) were determined by high-performance liquid chromatography (HPLC) with fluorometric detection. Binding to albumin (600 microM) varied from 61% (daunorubicin) to 94% (iododoxorubicin). The binding to alpha 1-acid glycoprotein (50 microM) was more variable, ranging from 31% (epirubicin) to 64% (zorubicin), and was essentially related to the hydrophobicity of the derivatives. Simulations showed that the total serum binding varied over a broad range from 71% (doxorubicin) to 96% (iododoxorubicin). We recently reported that the binding to lipoproteins of a series of eight anthracycline analogues could be ascribed to chemicophysical determinants of lipophilicity [2]. The present study was conducted to evaluate in vitro the contribution of albumin and alpha 1-acid glycoprotein to the total serum binding of these drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823501     DOI: 10.1007/s002800050529

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

Review 1.  Cardiovascular complications of breast cancer therapy in older adults.

Authors:  Chetan Shenoy; Igor Klem; Anna Lisa Crowley; Manesh R Patel; Mark A Winchester; Cynthia Owusu; Gretchen G Kimmick
Journal:  Oncologist       Date:  2011-07-07

2.  Protein nanocapsules containing doxorubicin as a pH-responsive delivery system.

Authors:  Dongmei Ren; Felix Kratz; Szu-Wen Wang
Journal:  Small       Date:  2011-03-29       Impact factor: 13.281

3.  Tobacco mosaic virus delivery of mitoxantrone for cancer therapy.

Authors:  Richard D Lin; Nicole F Steinmetz
Journal:  Nanoscale       Date:  2018-08-30       Impact factor: 7.790

4.  Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study.

Authors:  Anand S Patel; Maythem Saeed; Erin J Yee; Jeffrey Yang; Gregory J Lam; Aaron D Losey; Prasheel V Lillaney; Bradford Thorne; Albert K Chin; Sheena Malik; Mark W Wilson; Xi C Chen; Nitash P Balsara; Steven W Hetts
Journal:  J Med Device       Date:  2014-08-19       Impact factor: 0.582

5.  Tuning the In Vivo Transport of Anticancer Drugs Using Renal-Clearable Gold Nanoparticles.

Authors:  Chuanqi Peng; Jing Xu; Mengxiao Yu; Xuhui Ning; Yingyu Huang; Bujie Du; Elizabeth Hernandez; Payal Kapur; Jer-Tsong Hsieh; Jie Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2019-05-14       Impact factor: 15.336

Review 6.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

7.  Biomimetic Design of Protein Nanomaterials for Hydrophobic Molecular Transport.

Authors:  Dongmei Ren; Mercè Dalmau; Arlo Randall; Matthew M Shindel; Pierre Baldi; Szu-Wen Wang
Journal:  Adv Funct Mater       Date:  2012-04-23       Impact factor: 18.808

8.  CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration.

Authors:  Gillian Whitaker; Amy Lillquist; Stephanie A Pasas; Robert O'Connor; Fiona Regan; Craig E Lunte; Malcolm R Smyth
Journal:  J Sep Sci       Date:  2008-06       Impact factor: 3.645

9.  Pharmacokinetics of doxorubicin in pregnant women.

Authors:  Rachel J Ryu; Sara Eyal; Henry G Kaplan; Arezoo Akbarzadeh; Karen Hays; Kristin Puhl; Thomas R Easterling; Stacey L Berg; Kathleen A Scorsone; Eric M Feldman; Jason G Umans; Menachem Miodovnik; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-15       Impact factor: 3.333

Review 10.  Toxicity of Cancer Therapies in Older Patients.

Authors:  Olivia Le Saux; Claire Falandry
Journal:  Curr Oncol Rep       Date:  2018-06-13       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.